1887

Journal of General Virology header logo

Volume 93, Issue 3

The polio-eradication programme and issues of the end game Open Access

Abstract

Poliovirus causes paralytic poliomyelitis, an ancient disease of humans that became a major public-health issue in the 20th century. The primary site of infection is the gut, where virus replication is entirely harmless; the two very effective vaccines developed in the 1950s (oral polio vaccine, or OPV, and inactivated polio vaccine, or IPV) induce humoral immunity, which prevents viraemic spread and disease. The success of vaccination in middle-income and developing countries encouraged the World Health Organization to commit itself to an eradication programme, which has made great advances. The features of the infection, including its largely silent nature and the ability of the live vaccine (OPV) to evolve and change in vaccine recipients and their contacts, make eradication particularly challenging. Understanding the pathogenesis and virology of the infection is of major significance as the programme reaches its conclusion.

  • Published Online:
© 2012 SGM
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.036988-0
2012-03-01
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/93/3/457.html?itemId=/content/journal/jgv/10.1099/vir.0.036988-0&mimeType=html&fmt=ahah

References

  1. Abraham R., Minor P., Dunn G., Modlin J. F., Ogra P. L. 1993; Shedding of virulent poliovirus revertants during immunization with oral poliovirus vaccine after prior immunization with inactivated polio vaccine. J Infect Dis 168:1105–1109 [View Article][PubMed]
     [Google Scholar]
  2. Agol V. I., Belov G. A., Cherkasova E. A., Gavrilin G. V., Kolesnikova M. S., Romanova L. I., Tolskaya E. A. 2001; Some problems of molecular biology of poliovirus infection relevant to pathogenesis, viral spread and evolution. Dev Biol (Basel) 105:43–50[PubMed]
     [Google Scholar]
  3. Arita I., Nakane M., Fenner F. 2006; Public health. Is polio eradication realistic?. Science 312:852–854 [View Article][PubMed]
     [Google Scholar]
  4. Bodian D. 1955; Emerging concept of poliomyelitis infection. Science 122:105–108 [View Article][PubMed]
     [Google Scholar]
  5. Bouchard M. J., Lam D.-H., Racaniello V. R. 1995; Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine. J Virol 69:4972–4978[PubMed]
     [Google Scholar]
  6. Burns C. C., Shaw J., Campagnoli R., Jorba J., Vincent A., Quay J., Kew O. 2006; Modulation of poliovirus replicative fitness in HeLa cells by deoptimization of synonymous codon usage in the capsid region. J Virol 80:3259–3272 [View Article][PubMed]
     [Google Scholar]
  7. Burns C. C., Campagnoli R., Shaw J., Vincent A., Jorba J., Kew O. 2009; Genetic inactivation of poliovirus infectivity by increasing the frequencies of CpG and UpA dinucleotides within and across synonymous capsid region codons. J Virol 83:9957–9969 [View Article][PubMed]
     [Google Scholar]
  8. Buttinelli G., Donati V., Fiore S., Marturano J., Plebani A., Balestri P., Soresina A. R., Vivarelli R., Delpeyroux F. other authors 2003; Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis. J Gen Virol 84:1215–1221 [View Article][PubMed]
     [Google Scholar]
  9. Cammack N., Phillips A., Dunn G., Patel V., Minor P. D. 1988; Intertypic genomic rearrangements of poliovirus strains in vaccinees. Virology 167:507–514 [CrossRef]
     [Google Scholar]
  10. CDC 2009; Update on vaccine-derived polioviruses – worldwide, January 2008–June 2009. MMWR Morb Mortal Wkly Rep 58:1002–1006[PubMed]
     [Google Scholar]
  11. CDC 2011; Update on vaccine-derived polioviruses – worldwide, July 2009–March 2011. MMWR Morb Mortal Wkly Rep 60:846–850[PubMed]
     [Google Scholar]
  12. Cherkasova E., Laassri M., Chizhikov V., Korotkova E., Dragunsky E., Agol V. I., Chumakov K. 2003; Microarray analysis of evolution of RNA viruses: evidence of circulation of virulent highly divergent vaccine-derived polioviruses. Proc Natl Acad Sci U S A 100:9398–9403 [View Article][PubMed]
     [Google Scholar]
  13. Chumakov K., Ehrenfeld E., Wimmer E., Agol V. I. 2007; Vaccination against polio should not be stopped. Nat Rev Microbiol 5:952–958 [View Article][PubMed]
     [Google Scholar]
  14. Coleman J. R., Papamichail D., Skiena S., Futcher B., Wimmer E., Mueller S. 2008; Virus attenuation by genome-scale changes in codon pair bias. Science 320:1784–1787 [View Article][PubMed]
     [Google Scholar]
  15. Deshpande J. M., Nadkarni S. S., Siddiqui Z. A. 2003; Detection of MEF-1 laboratory reference strain of poliovirus type 2 in children with poliomyelitis in India in 2002 & 2003. Indian J Med Res 118:217–223
     [Google Scholar]
  16. DeVries A. S., Harper J., Murray A., Lexau C., Bahta L., Christensen J., Cebelinski E., Fuller S., Kline S. other authors 2011; Vaccine-derived poliomyelitis 12 years after infection in Minnesota. N Engl J Med 364:2316–2323 [View Article][PubMed]
     [Google Scholar]
  17. Dowdle W. R., Wolff C. 2006; Post-eradication poliovirus facility-associated community risks. Biologicals 34:127–132 [View Article][PubMed]
     [Google Scholar]
  18. Dragunsky E., Taffs R., Chernokhvostova Y., Nomura T., Hioki K., Gardner D., Norwood L., Levenbook I. 1996; A poliovirus-susceptible transgenic mouse model as a possible replacement for the monkey neurovirulence test of oral poliovirus vaccine. Biologicals 24:77–86 [View Article][PubMed]
     [Google Scholar]
  19. Dragunsky E. M., Ivanov A. P., Wells V. R., Ivshina A. V., Rezapkin G. V., Abe S., Potapova S. G., Enterline J. C., Hashizume S., Chumakov K. M. 2004; Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy. J Infect Dis 190:1404–1412 [View Article][PubMed]
     [Google Scholar]
  20. Dunn G., Begg N. T., Cammack N., Minor P. D. 1990; Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources. J Med Virol 32:92–95 [View Article][PubMed]
     [Google Scholar]
  21. El Bassioni L., Barakat I., Nasr E., de Gourville E. M., Hovi T., Blomqvist S., Burns C., Stenvik M., Gary H. other authors 2003; Prolonged detection of indigenous wild polioviruses in sewage from communities in Egypt. Am J Epidemiol 158:807–815 [View Article][PubMed]
     [Google Scholar]
  22. Evans D. M., Dunn G., Minor P. D., Schild G. C., Cann A. J., Stanway G., Almond J. W., Currey K., Maizel J. V. Jr 1985; Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature 314:548–550 [View Article][PubMed]
     [Google Scholar]
  23. Faden H., Modlin J. F., Thoms M. L., McBean A. M., Ferdon M. B., Ogra P. L. 1990; Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J Infect Dis 162:1291–1297 [View Article][PubMed]
     [Google Scholar]
  24. Filman D. J., Syed R., Chow M., Macadam A. J., Minor P. D., Hogle J. M. 1989; Structural factors that control conformational transitions and serotype specificity in type 3 poliovirus. EMBO J 8:1567–1579[PubMed]
     [Google Scholar]
  25. Fine P. E. M., Carneiro I. A. M. 1999; Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative. Am J Epidemiol 150:1001–1021[PubMed] [CrossRef]
     [Google Scholar]
  26. Grassly N. C., Wenger J., Durrani S., Bahl S., Deshpande J. M., Sutter R. W., Heymann D. L., Aylward R. B. 2007; Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case–control study. Lancet 369:1356–1362 [View Article][PubMed]
     [Google Scholar]
  27. Halsey N. A., Pinto J., Espinosa-Rosales F., Faure-Fontenla M. A., da Silva E., Khan A. J., Webster A. D. B., Minor P., Dunn G. other authors 2004; Search for poliovirus carriers among people with primary immune deficiency diseases in the United States, Mexico, Brazil, and the United Kingdom. Bull World Health Organ 82:3–8[PubMed]
     [Google Scholar]
  28. Hammon W. M., Coriell L. L., Wehrle P. F., Stokes J. Jr 1953; Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis. IV. Final report of results based on clinical diagnoses. J Am Med Assoc 151:1272–1285
     [Google Scholar]
  29. Hogle J. M., Chow M., Filman D. J. 1985; Three-dimensional structure of poliovirus at 2.9 Å resolution. Science 229:1358–1365 [View Article][PubMed]
     [Google Scholar]
  30. Jenkins P. C., Modlin J. F. 2006; Decision analysis in planning for a polio outbreak in the United States. Pediatrics 118:611–618 [View Article][PubMed]
     [Google Scholar]
  31. John J. 2009; Role of injectable and oral polio vaccines in polio eradication. Expert Rev Vaccines 8:5–8 [View Article][PubMed]
     [Google Scholar]
  32. Jorba J., Campagnoli R., De L., Kew O. 2008; Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range. J Virol 82:4429–4440 [View Article][PubMed]
     [Google Scholar]
  33. Jubelt B., Agre J. C. 2000; Characteristics and management of postpolio syndrome. JAMA 284:412–414 [View Article][PubMed]
     [Google Scholar]
  34. Kew O., Morris-Glasgow V., Landaverde M., Burns C., Shaw J., Garib Z., André J., Blackman E., Freeman C. J. other authors 2002; Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 296:356–359 [View Article][PubMed]
     [Google Scholar]
  35. Kluger J. 2004 Splendid Solution: Jonas Salk and the Conquest of Polio New York: Penguin;
     [Google Scholar]
  36. Koike S., Taya C., Kurata T., Abe S., Ise I., Yonekawa H., Nomoto A. 1991; Transgenic mice susceptible to poliovirus. Proc Natl Acad Sci U S A 88:951–955 [View Article][PubMed]
     [Google Scholar]
  37. Korotkova E. A., Park R., Cherkasova E. A., Lipskaya G. Y., Chumakov K. M., Feldman E. V., Kew O. M., Agol V. I. 2003; Retrospective analysis of a local cessation of vaccination against poliomyelitis: a possible scenario for the future. J Virol 77:12460–12465 [View Article][PubMed]
     [Google Scholar]
  38. Laassri M., Lottenbach K., Belshe R., Rennels M., Plotkin S., Chumakov K. 2006; Analysis of reversions in the 5′-untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines. J Infect Dis 193:1344–1349 [View Article][PubMed]
     [Google Scholar]
  39. Landsteiner K., Popper E. 1909; Übertragung der Poliomyelitis acuta auf Affen. Z Immunitaetsforsch Exp Ther 2:377–390 in German
    [Google Scholar]
  40. Lapinleimu K. 1984; Elimination of poliomyelitis in Finland. Rev Infect Dis 6:Suppl. 2S457–S460 [View Article][PubMed]
     [Google Scholar]
  41. Lukashev A. N., Lashkevich V. A., Ivanova O. E., Koroleva G. A., Hinkkanen A. E., Ilonen J. 2003; Recombination in circulating enteroviruses. J Virol 77:10423–10431 [View Article][PubMed]
     [Google Scholar]
  42. Macadam A. J., Ferguson G., Arnold C., Minor P. D. 1991; An assembly defect as a result of an attenuating mutation in the capsid proteins of the poliovirus type 3 vaccine strain. J Virol 65:5225–5231[PubMed]
     [Google Scholar]
  43. Macadam A. J., Ferguson G., Burlison J., Stone D., Skuce R., Almond J. W., Minor P. D. 1992; Correlation of RNA secondary structure and attenuation of Sabin vaccine strains of poliovirus in tissue culture. Virology 189:415–422 [View Article][PubMed]
     [Google Scholar]
  44. Macadam A. J., Ferguson G., Stone D. M., Meredith J., Knowlson S., Auda G., Almond J. W., Minor P. D. 2006; Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication. J Virol 80:8653–8663 [View Article][PubMed]
     [Google Scholar]
  45. MacCallum F. O. 1971; Hypogammaglobulinaemia in the United Kingdom. VII. The role of humoral antibodies in protection against and recovery from bacterial and virus infections in hypogammaglobulinaemia. Spec Rep Ser Med Res Counc (G B) 310:72–85[PubMed]
     [Google Scholar]
  46. MacLennan C., Dunn G., Huissoon A. P., Kumararatne D. S., Martin J., O’Leary P., Thompson R. A., Osman H., Wood P. other authors 2004; Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet 363:1509–1513 [View Article][PubMed]
     [Google Scholar]
  47. Manor Y., Handsher R., Halmut T., Neuman M., Bobrov A., Rudich H., Vonsover A., Shulman L., Kew O. M., Mendelson E. 1999; Detection of poliovirus circulation by environmental surveillance in the absence of clinical cases in Israel and the Palestinian authority. J Clin Microbiol 37:1670–1675[PubMed]
     [Google Scholar]
  48. Martín J., Ferguson G. L., Wood D. J., Minor P. D. 2000a; The vaccine origin of the 1968 epidemic of type 3 poliomyelitis in Poland. Virology 278:42–49 [View Article][PubMed]
     [Google Scholar]
  49. Martín J., Dunn G., Hull R., Patel V., Minor P. D. 2000b; Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion. J Virol 74:3001–3010 [View Article][PubMed]
     [Google Scholar]
  50. Martín J., Crossland G., Wood D. J., Minor P. D. 2003; Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains. J Gen Virol 84:1781–1788 [View Article][PubMed]
     [Google Scholar]
  51. Martín J., Odoom K., Tuite G., Dunn G., Hopewell N., Cooper G., Fitzharris C., Butler K., Hall W. W., Minor P. D. 2004; Long-term excretion of vaccine-derived poliovirus by a healthy child. J Virol 78:13839–13847 [View Article][PubMed]
     [Google Scholar]
  52. Más Lago P., Gary H. E. Jr, Pérez L. S., Cáceres V., Olivera J. B., Puentes R. P., Corredor M. B., Jímenez P., Pallansch M. A., Cruz R. G. 2003; Poliovirus detection in wastewater and stools following an immunization campaign in Havana, Cuba. Int J Epidemiol 32:772–777 [View Article][PubMed]
     [Google Scholar]
  53. McGoldrick A., Macadam A. J., Dunn G., Rowe A., Burlison J., Minor P. D., Meredith J., Evans D. J., Almond J. W. 1995; Role of mutations G-480 and C-6203 in the attenuation phenotype of Sabin type 1 poliovirus. J Virol 69:7601–7605[PubMed]
     [Google Scholar]
  54. Mendelsohn C. L., Wimmer E., Racaniello V. R. 1989; Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell 56:855–865 [View Article][PubMed]
     [Google Scholar]
  55. Minor P. D. 1982; Characterization of strains of type 3 poliovirus by oligonucleotide mapping. J Gen Virol 59:307–317 [View Article][PubMed]
     [Google Scholar]
  56. Minor P. D. 1992; The molecular biology of poliovaccines. J Gen Virol 73:3065–3077 [View Article][PubMed]
     [Google Scholar]
  57. Minor P. D. 1997a; Poliovirus. In Viral Pathogenesis pp. 555–574 Edited by Nathanson N., Ahmed R., Ganzalez-Scarano F., Griffin D. E., Holmes K. V., Murphy F. A., Robinson H. L. Philadelphia, PA: Lippincott–Raven;
     [Google Scholar]
  58. Minor P. D. 1997b; Immunization of pregnant women could protect babies from vaccine associated poliomyelitis. Vaccine 15:1709 [View Article][PubMed]
     [Google Scholar]
  59. Minor P. D., Kew O., Schild G. C. 1982; Poliomyelitis – epidemiology, molecular biology and immunology. Nature 299:109–110 [View Article][PubMed]
     [Google Scholar]
  60. Minor P. D., John A., Ferguson M., Icenogle J. P. 1986; Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccinee. J Gen Virol 67:693–706 [View Article][PubMed]
     [Google Scholar]
  61. Minor P. D., Dunn G., Evans D. M., Magrath D. I., John A., Howlett J., Phillips A., Westrop G., Wareham K. other authors 1989; The temperature sensitivity of the Sabin type 3 vaccine strain of poliovirus: molecular and structural effects of a mutation in the capsid protein VP3. J Gen Virol 70:1117–1123 [View Article][PubMed]
     [Google Scholar]
  62. Minor P. D., Dunn G., Ramsay M. E., Brown D. 2005; Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains. J Med Virol 75:153–160 [View Article][PubMed]
     [Google Scholar]
  63. Mueller S., Papamichail D., Coleman J. R., Skiena S., Wimmer E. 2006; Reduction of the rate of poliovirus protein synthesis through large-scale codon deoptimization causes attenuation of viral virulence by lowering specific infectivity. J Virol 80:9687–9696 [View Article][PubMed]
     [Google Scholar]
  64. Mulders M. N., Reimerink J. H. J., Koopmans M. P. G., van Loon A. M., van der Avoort H. G. A. M. 1997; Genetic analysis of wild-type poliovirus importation into The Netherlands (1979–1995). J Infect Dis 176:617–624 [View Article][PubMed]
     [Google Scholar]
  65. Nathanson N. 1984; Epidemiologic aspects of poliomyelitis eradication. Rev Infect Dis 6:Suppl. 2S308–S312 [View Article][PubMed]
     [Google Scholar]
  66. Nathanson N. 2008; The pathogenesis of poliomyelitis: what we don’t know. Adv Virus Res 71:1–50 [View Article][PubMed]
     [Google Scholar]
  67. Nkowane B. M., Wassilak S. G., Orenstein W. A., Bart K. J., Schonberger L. B., Hinman A. R., Kew O. M. 1987; Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. JAMA 257:1335–1340 [View Article][PubMed]
     [Google Scholar]
  68. Nomoto A., Omata T., Toyoda H., Kuge S., Horie H., Kataoka Y., Genba Y., Nakano Y., Imura N. 1982; Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome. Proc Natl Acad Sci U S A 79:5793–5797 [View Article][PubMed]
     [Google Scholar]
  69. Nottay B. K., Kew O. M., Hatch M. H., Heyward J. T., Obijeski J. F. 1981; Molecular variation of type 1 vaccine-related and wild polioviruses during replication in humans. Virology 108:405–423 [View Article][PubMed]
     [Google Scholar]
  70. Ofosu-Amaah S. 1984; The challenge of poliomyelitis in tropical Africa. Rev Infect Dis 6:Suppl. 2S318–S320 [View Article][PubMed]
     [Google Scholar]
  71. Ohka S., Igarashi H., Nagata N., Sakai M., Koike S., Nochi T., Kiyono H., Nomoto A. 2007; Establishment of a poliovirus oral infection system in human poliovirus receptor-expressing transgenic mice that are deficient in alpha/beta interferon receptor. J Virol 81:7902–7912 [View Article][PubMed]
     [Google Scholar]
  72. Omata T., Kohara M., Kuge S., Komatsu T., Abe S., Semler B. L., Kameda A., Itoh H., Arita M. other authors 1986; Genetic analysis of the attenuation phenotype of poliovirus type 1. J Virol 58:348–358[PubMed]
     [Google Scholar]
  73. Oostvogel P. M., van Wijngaarden J. K., van der Avoort H. G., Mulders M. N., Conyn-van Spaendonck M. A. E., Rümke H. C., van Steenis G., van Loon A. M. 1994; Poliomyelitis outbreak in an unvaccinated community in The Netherlands, 1992–93. Lancet 344:665–670 [View Article][PubMed]
     [Google Scholar]
  74. Paul J. R. 1971 A History of Poliomyelitis New Haven, CT: Yale University Press;
     [Google Scholar]
  75. Pelletier J., Sonenberg N. 1988; Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature 334:320–325 [View Article][PubMed]
     [Google Scholar]
  76. Pollard S. R., Dunn G., Cammack N., Minor P. D., Almond J. W. 1989; Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine. J Virol 63:4949–4951[PubMed]
     [Google Scholar]
  77. Pöyry T., Stenvik M., Hovi T. 1988; Viruses in sewage waters during and after a poliomyelitis outbreak and subsequent nationwide oral poliovirus vaccination campaign in Finland. Appl Environ Microbiol 54:371–374[PubMed]
     [Google Scholar]
  78. Racaniello V. R., Baltimore D. 1981; Cloned poliovirus complementary DNA is infectious in mammalian cells. Science 214:916–919 [View Article][PubMed]
     [Google Scholar]
  79. Ren R. B., Costantini F., Gorgacz E. J., Lee J. J., Racaniello V. R. 1990; Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis. Cell 63:353–362 [View Article][PubMed]
     [Google Scholar]
  80. Rico-Hesse R., Pallansch M. A., Nottay B. K., Kew O. M. 1987; Geographic distribution of wild poliovirus type 1 genotypes. Virology 160:311–322 [View Article][PubMed]
     [Google Scholar]
  81. Rowe A., Ferguson G. L., Minor P. D., Macadam A. J. 2000; Coding changes in the poliovirus protease 2A compensate for 5′NCR domain V disruptions in a cell-specific manner. Virology 269:284–293 [View Article][PubMed]
     [Google Scholar]
  82. Sabin A. B. 1956; Pathogenesis of poliomyelitis; reappraisal in the light of new data. Science 123:1151–1157 [View Article][PubMed]
     [Google Scholar]
  83. Sabin A. B. 1986; Strategy for rapid elimination and continuing control of poliomyelitis and other vaccine preventable diseases of children in developing countries. Br Med J (Clin Res Ed) 292:531–533 [View Article][PubMed]
     [Google Scholar]
  84. Sabin A. B., Boulger L. R. 1973; History of Sabin attenuated poliovirus oral live vaccine strains. J Biol Stand 1:115–118 [View Article]
     [Google Scholar]
  85. Savilahti E., Klemola T., Carlsson B., Mellander L., Stenvik M., Hovi T. 1988; Inadequacy of mucosal IgM antibodies in selective IgA deficiency: excretion of attenuated polio viruses is prolonged. J Clin Immunol 8:89–94 [View Article][PubMed]
     [Google Scholar]
  86. Shahmahmoodi S., Parvaneh N., Burns C., Asghar H., Mamishi S., Tabatabaie H., Chen Q., Teimourian S., Gooya M. M. other authors 2008; Isolation of a type 3 vaccine-derived poliovirus (VDPV) from an Iranian child with X-linked agammaglobulinemia. Virus Res 137:168–172 [View Article][PubMed]
     [Google Scholar]
  87. Shulman L. M., Manor Y., Handsher R., Delpeyroux F., McDonough M. J., Halmut T., Silberstein I., Alfandari J., Quay J. other authors 2000; Molecular and antigenic characterization of a highly evolved derivative of the type 2 oral poliovaccine strain isolated from sewage in Israel. J Clin Microbiol 38:3729–3734[PubMed]
     [Google Scholar]
  88. Simizu B., Abe S., Yamamoto H., Tano Y., Ota Y., Miyazawa M., Horie H., Satoh K., Wakabayashi K. 2006; Development of inactivated poliovirus vaccine derived from Sabin strains. Biologicals 34:151–154 [View Article][PubMed]
     [Google Scholar]
  89. Svitkin Y. V., Cammack N., Minor P. D., Almond J. W. 1990; Translation deficiency of the Sabin type 3 poliovirus genome: association with an attenuating mutation C472→U. Virology 175:103–109 [View Article][PubMed]
     [Google Scholar]
  90. Tambini G., Andrus J. K., Marques E., Boshell J., Pallansch M., de Quadros C. A., Kew O. M. 1993; Direct detection of wild poliovirus circulation by stool surveys of healthy children and analysis of community wastewater. J Infect Dis 168:1510–1514 [View Article][PubMed]
     [Google Scholar]
  91. Tebbens R. J., Pallansch M. A., Kew O. M., Cáceres V. M., Jafari H., Cochi S. L., Sutter R. W., Aylward R. B., Thompson K. M. 2006; Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal 26:1471–1505 [View Article][PubMed]
     [Google Scholar]
  92. Tebbens R. J., Pallansch M. A., Alexander J. P., Thompson K. M. 2010; Optimal vaccine stockpile design for an eradicated disease: application to polio. Vaccine 28:4312–4327 [View Article][PubMed]
     [Google Scholar]
  93. Thompson K. M., Tebbens R. J. 2007; Eradication versus control for poliomyelitis: an economic analysis. Lancet 369:1363–1371 [View Article][PubMed]
     [Google Scholar]
  94. Vignuzzi M., Stone J. K., Arnold J. J., Cameron C. E., Andino R. 2006; Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 439:344–348 [View Article][PubMed]
     [Google Scholar]
  95. Westdijk J., Brugmans D., Martin J., van’t Oever A., Bakker W. A. M., Levels L., Kersten G. 2011; Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines. Vaccine 29:3390–3397 [View Article][PubMed]
     [Google Scholar]
  96. WHO 1988; Global eradication of poliomyelitis by the year 2000 (World Health Assembly resolution WHA 41–28). http://www.polioeradication.org/content/publications/19880513_resolution.pdf
  97. WHO 2011a; Poliomyelitis. http://www.who.int/topics/poliomyelitis/en
  98. WHO 2011b; Reported estimates of immunization coverage time series. http://www.who.int/entity/immunization_monitoring/data/coverage_series.xls
  99. Wimmer E., Paul A. V. 2011; Synthetic poliovirus and other designer viruses: what have we learned from them?. Annu Rev Microbiol 65:583–609 [View Article][PubMed]
     [Google Scholar]
  100. Yang C. F., Naguib T., Yang S.-J., Nasr E., Jorba J., Ahmed N., Campagnoli R., van der Avoort H., Shimizu H. other authors 2003; Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993. J Virol 77:8366–8377 [View Article][PubMed]
     [Google Scholar]
  101. Yang C. F., Chen H. Y., Jorba J., Sun H. C., Yang S. J., Lee H. C., Huang Y. C., Lin T. Y., Chen P. J. other authors 2005; Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient. J Virol 79:12623–12634 [View Article][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.036988-0
Loading
The polio-eradication programme and issues of the end game
J. Gen. Virol. 93, 457 (2012); https://doi.org/10.1099/vir.0.036988-0
/content/journal/jgv/10.1099/vir.0.036988-0
/content/journal/jgv/10.1099/vir.0.036988-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error